Ownership Submission
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Cave James L.
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-05-04
|
3. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [TDOC]
|
|
(Last)
|
(First)
|
(Middle)
|
|
C/O TELADOC HEALTH, INC., , 2 MANHATTANVILLE ROAD, SUITE 203
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
INTERIM CAO /
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
|
(Street)
|
|
PURCHASE
|
NY
|
10577
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Cave James L.
C/O TELADOC HEALTH, INC.,
2 MANHATTANVILLE ROAD, SUITE 203
PURCHASE, NY10577
|
|
|
INTERIM CAO
|
|
Signatures
|
/s/ Adam C. Vandervoort, Attorney-in-Fact
|
2024-05-06
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
The option vested as to 25% of the shares on November 1, 2022. The remainder of the shares vest in 36 substantially equal monthly installments thereafter.
|
|
(2)
|
On November 1, 2021, the reporting person was granted 660 restricted stock units, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.
|
|
(3)
|
Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
|
|
(4)
|
On April 1, 2022, the reporting person was granted 4,067 restricted stock units, vesting one-third on March 1, 2023, with the remainder vesting in eight substantially equal quarterly installments thereafter.
|
|
(5)
|
On June 1, 2022, the reporting person was granted 4,598 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
|
|
(6)
|
On June 1, 2022, the reporting person was granted 4,002 restricted stock units, vesting in four substantially equal semiannual installments beginning on the six-month anniversary of the grant date.
|
|
(7)
|
On March 3, 2023, the reporting person was granted 13,951 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
|
|
(8)
|
On March 1, 2024, the reporting person was granted 15,000 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
